Microperimetry could provide extra info on macula function

Article

Microperimetry may provide additional information on macula function that is not available using visual acuity data.

Microperimetry may provide additional information on macula function that is not available using visual acuity data, according to a study in Retina.

A team led by Dr M. Parravano, Fondazione G.B. Bietti-IRCCS, Rome, Italy, evaluated 18 neovascular AMD patients in a retrospective 24-week follow-up study. All patients received three injections of ranibizumab 0.5 mg one month apart and were retreated according to predefined criteria.

Baseline measurements included visual acuity, fluorescein angiography, microperimetry and optical coherence tomography stratus. Measurements for visual acuity, microperimetry and OCT evaluations were also conducted 28 days after each injection.

Mean retinal sensitivity significantly improved from a baseline of 3.89 ± 3.0 dB to 6.61 ± 3.4 dB at 24 weeks. Mean visual acuity improved from 48.67 ± 8.58 to 60.72 ± 16.09, with 44.4% of patients gaining 15 letters or more and 38.9% gaining a mean of 6.14 ± 3.7 letters. However, 16.7% of patients lost a mean of 7.3 ± 2.1 letters.

Fixation stability improved from baseline in 33.3% of patients and central macula thickness significantly decreased from 310.5 ± 85.7 µ to 217.3 ± 46.8 µ at 24 weeks.

Overall, visual acuity and retinal thickness changes appeared to peak at four weeks after the administration of intravitreal ranibizumab 0.5 mg. Retinal sensitivity measured by microperimetry presented a trend of progressive improvement until 24 weeks.

To read the abstract please click here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.